Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights.
Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Foghorn Therapeutics Company is mentioned.
We assess its relevance and importance to carry out an overall sentiment valuation of Foghorn Therapeutics Inc. (FHTX).
You can view the trend designation for each individual article below.
We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Foghorn Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Foghorn Therapeutics Inc. (FHTX)
March 19, 2024 (12:30) / "PR Newswire" (by Flagship Pioneering)
Ranked #3 Most Innovative Company in North America Recognized for the Third Consecutive Year CAMBRIDGE, Mass., March 19, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of ...
Foghorn Therapeutics Inc. (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The consensus price target hints at a 124.3% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 27.85% and 17.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend:Neutral
March 5, 2024 (21:48) / "Benzinga" (by Globe Newswire)
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024 Oral presentation demonstrating preclinical efficacy and tolerability data for Selective CBP and Selective ...
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC. IND filing planned in ...
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
In Article Trend:Somewhat-Bullish
February 28, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Foghorn Therapeutics Inc. FHTX shares are trading higher by 44.8% to $4.52 during Thursday's session after the company announced that Eli Lilly And Co LLY has chosen FHD-909, an oral BRM selective inhibitor, for clinical development. Foghorn says the drug targets BRG1 mutated non-small cell lung ...
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and,
moreover, are not trading signals.
When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market
as a result of using the information contained on the site.
This website uses cookies to ensure you get the best experience on our website